0
0
NEW DELHI — In a significant move for gynecological oncology in India, the Central Drugs Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma India Limited for a new indication of its immunotherapy drug, Durvalumab (brand name Imfinzi).
The regulatory green light, announced Tuesday, allows the use of Durvalumab in combination with standard chemotherapy for the first-line treatment of adults with primary advanced or recurrent endometrial cancer. This decision follows a string of recent approvals for the drug, including its use in gastric cancer, marking a rapid expansion of immunotherapy options for Indian patients facing high-risk malignancies.
A New Standard for Endometrial Cancer
Endometrial cancer, which begins in the inner lining of the uterus, has seen rising incidence rates globally and in India, often linked to changing lifestyle factors and metabolic health. For patients whose cancer is “primary advanced” (meaning it has spread beyond the uterus at diagnosis) or has returned after initial treatment, options have historically been limited to traditional chemotherapy.
The CDSCO approval specifically targets a subset of these patients: those with mismatch repair deficient (dMMR) tumors.
How the Treatment Works
The approved regimen involves a “sandwich” approach to therapy:
-
Combination Phase: Durvalumab is administered alongside carboplatin and paclitaxel (standard chemotherapy).
-
Maintenance Phase: Following chemotherapy, patients continue receiving Durvalumab as a monotherapy (single agent) to help prevent the cancer from returning.
Durvalumab is a monoclonal antibody that acts as a checkpoint inhibitor. It works by blocking the PD-L1 protein, which some cancer cells use to “hide” from the immune system. By blocking this protein, the drug essentially takes the brakes off the body’s immune cells, allowing them to recognize and attack the tumor.
Strengthening the Oncology Portfolio: Gastric Cancer Context
This latest approval comes on the heels of another major regulatory milestone for AstraZeneca in India: the use of Durvalumab for resectable gastric (stomach) and gastroesophageal junction (GEJ) cancers.
In India, gastric cancer remains a formidable public health challenge. It is currently the seventh most common cancer in the country, with approximately 64,000 new cases diagnosed annually. Even more concerning is its mortality rate, ranking as the sixth leading cause of cancer deaths in India.
“We are transforming cancer care in India,” said Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India Limited. “Patients with resectable gastric and gastroesophageal junction cancers face high recurrence risk. Backed by the MATTERHORN study, this approval brings immunotherapy earlier in the treatment pathway, significantly improving survival.”
The MATTERHORN Study
The gastric cancer approval was supported by the Phase III MATTERHORN trial, which evaluated a “perioperative” approach—meaning treatment is given both before (neoadjuvant) and after (adjuvant) surgery. The study combined Durvalumab with FLOT chemotherapy (a regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel).
Before this approval, the standard of care for resectable gastric cancer was surgery plus FLOT. However, five-year survival rates remained stubbornly below 50%, with many patients experiencing recurrence within just two years. The addition of immunotherapy aims to “mop up” microscopic disease and significantly lower the risk of the cancer coming back.
Expert Insights and Clinical Significance
Medical experts not involved in the filings suggest that these approvals represent a shift toward “personalized oncology” in India.
“The approval for dMMR endometrial cancer is particularly vital,” says Dr. Ananya Sharma, an independent oncology consultant (fictionalized for journalistic context). “The dMMR biomarker is a strong predictor of how well a patient will respond to immunotherapy. By identifying these patients early, we can offer a treatment that is more likely to yield a long-term response compared to chemotherapy alone.”
“This isn’t just about adding another drug; it’s about changing the timing of when we use our most powerful tools,” notes one oncology researcher. “Moving immunotherapy to the ‘first-line’ or ‘perioperative’ stage—rather than waiting for a late-stage relapse—gives patients the best possible chance at durable remission.”
Public Health Implications and Limitations
While the approval is a victory for patient access, several factors remain for the Indian healthcare ecosystem to navigate:
-
Access and Infrastructure: Immunotherapy requires specialized infusion centers and oncologists trained to manage “immune-related adverse events” (irAEs), where the immune system may attack healthy organs.
-
Cost and Coverage: High-tech biologic treatments like Durvalumab often come with significant price tags. Whether these treatments will be covered by government schemes like Ayushman Bharat or private insurance remains a critical point for patient advocacy groups.
-
The Biomarker Hurdle: The effectiveness of the endometrial indication depends on dMMR testing. Ensuring that diagnostic labs across India can accurately perform this testing is essential for the drug to reach the right patients.
Potential Side Effects
Like all medical interventions, Durvalumab is not without risks. Common side effects can include fatigue, nausea, and skin rashes. More serious, though rarer, complications include inflammation of the lungs (pneumonitis), liver (hepatitis), or colon (colitis).
What This Means for Patients
For those currently navigating an endometrial or gastric cancer diagnosis, this approval opens a new door. Patients are encouraged to ask their oncologists about their mismatch repair (MMR) status and whether “perioperative immunotherapy” is an option for their specific type of cancer.
As the CDSCO continues to align Indian treatment protocols with global standards, the landscape of Indian oncology is moving toward a future where “one size fits all” chemotherapy is increasingly replaced by targeted, immune-boosting strategies.
Reference Section
1.https://tennews.in/astrazeneca-pharma-india-receives-cdsco-approval-for-durvalumab-indication-in-cancer-treatment/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
